Home » Newsletters » BioWorld Science

BioWorld Science

March 22, 2012

View Archived Issues

Merck & Co. uncovers gene polymorphisms linked to MK-7246 pharmacokinetics

Fate Therapeutics discloses new hedgehog pathway activators

Canadian university patents new SHIP-1 modulators

Novartis discloses updated phase II data on secukinumab

Cardium Therapeutics begins phase III registration study

Korean trials assess two Lapscovery-based drugs

Galapagos receives milestone payment from Janssen Pharmaceutica

Addex Pharmaceuticals changes name

Ablynx extends global strategic Nanobody alliance

Abbott discloses new name for future research-based company

Medistem updates on endometrial regenerative cell therapy development

Treatment begins in global phase II/III hemophilia B trial

Flagyl approved for additional indication in Japan

NCI study reveals novel candidate biomarkers of hepatocellular carcinoma

Health Canada approves grass pollen immunotherapy

Green Cross clear to conduct GreenGene F study in U.S.

Merck & Co. presents new potential cancer therapies

Novel chemokine CCR4 receptor antagonists developed at GSK

New tyrosine-protein kinase inhibitors reported

Chroma Therapeutics designs new histone deacetylase inhibitors

Allergan scientists discover novel prostanoid receptor antagonists

Cerus gives update on INTERCEPT Blood System

Line extension for Taxol approved in Japan

Enrollment complete in phase II MN-221 trial

Noven completes phase III program for low-dose paroxetine mesilate

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...